Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $408 | $388 | $184 | $157 |
| % Growth | 5.1% | 111.4% | 16.8% | – |
| Cost of Goods Sold | $161 | $170 | $157 | $254 |
| Gross Profit | $247 | $219 | $27 | $170 |
| % Margin | 60.6% | 56.3% | 14.6% | 108.3% |
| R&D Expenses | $19 | $22 | $16 | $25 |
| G&A Expenses | $115 | $56 | $58 | -$29 |
| SG&A Expenses | $251 | $186 | $184 | $182 |
| Sales & Mktg Exp. | $137 | $131 | $126 | $105 |
| Other Operating Expenses | $0 | $150 | $14 | $0 |
| Operating Expenses | $271 | $358 | $213 | $207 |
| Operating Income | -$24 | -$139 | -$186 | -$136 |
| % Margin | -5.8% | -35.8% | -101.6% | -86.3% |
| Other Income/Exp. Net | -$60 | -$51 | -$83 | -$10 |
| Pre-Tax Income | -$83 | -$190 | -$270 | -$146 |
| Tax Expense | $7 | -$21 | $48 | $75 |
| Net Income | -$94 | -$174 | $117 | -$209 |
| % Margin | -23% | -44.9% | 63.9% | -133.3% |
| EPS | -1.14 | -2.12 | -3.85 | -3.2 |
| % Growth | 46.2% | 44.9% | -20.3% | – |
| EPS Diluted | -1.14 | -2.12 | -3.67 | -3.2 |
| Weighted Avg Shares Out | 82 | 82 | 82 | 82 |
| Weighted Avg Shares Out Dil | 79 | 80 | 86 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $7 | $0 |
| Interest Expense | $35 | $35 | $10 | $32 |
| Depreciation & Amortization | $64 | $68 | $67 | $76 |
| EBITDA | $42 | -$87 | -$174 | -$46 |
| % Margin | 10.3% | -22.4% | -95% | -29.5% |